Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial-Reference-Cited by-同舟云学术

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial

Published:2016-06-10 Issue:10 Volume:18 Page:1228-1234
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Vardeny Orly¹,Claggett Brian²,Packer Milton³,Zile Michael R.⁴,Rouleau Jean⁵,Swedberg Karl⁶,Teerlink John R.⁷,Desai Akshay S.²,Lefkowitz Martin⁸,Shi Victor⁸,McMurray John J.V.⁹,Solomon Scott D.²,

Affiliation:

1. Pharmacy Practice Division University of Wisconsin School of Pharmacy Madison WI USA

2. Cardiovascular Division Brigham and Women's Hospital Boston MA USA

3. Division of Cardiology; Baylor Heart and Vascular Institute Baylor University Medical Center Dallas USA

4. Medical University of South Carolina and Ralph H. Johnston Veterans Administration Medical Center Charleston NC USA

5. Institut de Cardiologie de Montreal Université de Montréal Montreal Canada

6. University of Gothenburg, Gothenburg Sweden and National Heart and Lung Institute, Imperial College London UK

7. University of California‐San Francisco and San Francisco Veterans Affairs Medical Center San Francisco CA USA

8. Novartis Pharmaceuticals Corporation East Hanover New Jersey USA

9. British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.580

Reference13 articles.

1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure

3. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

4. Effects of Enalapril on Mortality in Severe Congestive Heart Failure

5. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring;Journal of Cardiovascular Medicine;2024-01-23

2. Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity;Biochemical and Biophysical Research Communications;2024-01

3. Clinical trials for Chagas disease: etiological and pathophysiological treatment;Frontiers in Microbiology;2023-12-15

4. Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF;ESC Heart Failure;2023-12

5. Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions;High Blood Pressure & Cardiovascular Prevention;2023-11-18